These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. Cao SN; Chang KH; Luthra R; Liu J Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989 [TBL] [Abstract][Full Text] [Related]
10. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Shannon C; Kirk J; Barnetson R; Evans J; Schnitzler M; Quinn M; Hacker N; Crandon A; Harnett P Clin Cancer Res; 2003 Apr; 9(4):1387-92. PubMed ID: 12684409 [TBL] [Abstract][Full Text] [Related]
11. [Dualistic model of molecular pathogenesis in endometrial carcinoma]. Lax SF Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308 [TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706 [TBL] [Abstract][Full Text] [Related]
13. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416 [TBL] [Abstract][Full Text] [Related]
16. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566 [TBL] [Abstract][Full Text] [Related]
17. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Lax SF Pathology; 2007 Feb; 39(1):46-54. PubMed ID: 17365822 [TBL] [Abstract][Full Text] [Related]
18. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657 [TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230 [TBL] [Abstract][Full Text] [Related]
20. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]